You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
Using Genotype-Tissue Expression project samples, researchers put together gene regulatory networks for 29 tissue types, uncovering extensive sex-related regulatory differences.
The Bay Area startup is offering a no-touch method to separate cell populations for downstream analysis in genomics and synthetic biology applications.
In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.
The firm said its test is one-thousandfold more sensitive than conventional SARS-CoV-2 serology tests and could enable earlier antibody detection in patients.
The biobank will collect samples and data from Biogen employees who contracted and have recovered from COVID-19, as well as their family members and close contacts.
The clinics see patients whose overall health may benefit from learning about their genetic predisposition for certain medical conditions.
Understanding the genetic causes of hypercholesterolemia could provide prognostic information to help treat patients, the researchers said.
In PNAS this week: gene-edited mouse model of small cell lung cancer, cystic fibrosis carrier-related conditions, and more.
Using systems biology, investigators put cancer risk SNPs in a network context, identifying immune, tumor-related, and other genes influenced by the variants in multiple tissue types.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.